Constellation Pharmaceuticals Completes Management Team with Key Leadership Appointments

Emma Reeve Joins as Chief Financial Officer, Brad Prosek as Senior Vice President, Corporate Development

Key Hires Bolster Company’s Finance, Business Development and Commercialization Efforts

CAMBRIDGE, Mass.--()--Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics, today announced it has appointed Emma Reeve as chief financial officer and Brad Prosek as senior vice president, corporate development.

“The next 12-24 months will be a transformational period for Constellation as we advance our pipeline toward late-stage development. Emma and Brad each bring highly relevant experiences to Constellation, including capital markets expertise, business development, and the commercialization of novel therapies,” said Jigar Raythatha, president and chief executive officer of Constellation Pharmaceuticals. “This past summer we re-organized our R&D leadership and recruiting Emma and Brad provides pivotal business leadership as we chart our path forward.”

Emma Reeve is a global finance executive who has worked in healthcare for over 20 years across pharmaceutical, medical device and bio-pharma companies. Prior to joining Constellation Pharmaceuticals, Emma served as interim chief financial officer and corporate controller of PAREXEL International, where she was responsible for all aspects of financial reporting and accounting, investor relations, financial planning and analysis. Previously, Emma held senior finance roles at major pharma companies including Novartis, Merck and Bristol-Myers Squibb. Emma was also the chief financial officer of two development-stage biotech companies, Inotek Pharmaceuticals and Aton Pharma. In addition to finance, Emma has held senior positions in a number of countries in areas such as marketing, supply chain management and research operations.

Brad Prosek joins Constellation Pharmaceuticals from All Terrain bioPartners LLC, where he advised and supported a global set of life sciences clients on transaction, corporate and commercial strategy as well as execution. Previously, he spent 10 years at Cubist Pharmaceuticals, where he built the company’s Market Access strategy and organization, led transaction teams responsible for deals, including the acquisition of Trius Therapeutics, supporting the company’s pipeline growth and led a new corporate venture building a complementary infection prevention business. Prior to Cubist, Brad served in growing commercial operations and market / business development roles at Biogen, and worked as a health economics and reimbursement strategy consultant with Covance in the United States and Europe.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics. With a decade of experience in the field, the company has an unparalleled understanding of how chromatin biology modulates gene expression. Constellation is translating these insights to advance the company’s two lead clinical programs, EZH2 and BET, and in novel targets for which cancer epigenetics plays a central role.

For more information, please visit www.constellationpharma.com.

Note to editors:

Photos available upon request.

Contacts

Pure Communications, Inc.
Katie Engleman, +1 910-509-3977
katie@purecommunicationsinc.com

Contacts

Pure Communications, Inc.
Katie Engleman, +1 910-509-3977
katie@purecommunicationsinc.com